Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination
NCT ID: NCT01441609
Last Updated: 2011-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
94 participants
OBSERVATIONAL
2011-08-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the value of anti-HBs =0 mIU/ml
Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
No interventions assigned to this group
the value of anti-HBs≤5mIU/ml
Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
No interventions assigned to this group
5mIU≤anti-HBs≤10mIU/ml
Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
No interventions assigned to this group
anti-HBs≥1000mIU
Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* between 3-60 years old
* healthy
* have the history of vaccination of hepatitis B.
* Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative.
* informed consent
* not allergic to the component of the vaccine
3 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Municipal Science & Technology Commission
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wu Jiang
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wu Jiang
Role: STUDY_DIRECTOR
main investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chifeng, Inner Mongolia, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Li xuezhen
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BJCDCWJ201103
Identifier Type: -
Identifier Source: org_study_id